Triglav Skladi’s ResMed RMD Stock Holding History

Triglav Skladi’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.44M	Hold	6,400	–	–	0.1%	108
2025 Q4	$1.54M	Sell	6,400 -1,000	-14%	-$256K	0.1%	105
2025 Q3	$2.03M	Hold	7,400	–	–	0.13%	78
2025 Q2	$1.91M	Hold	7,400	–	–	0.14%	79
2025 Q1	$1.66M	Hold	7,400	–	–	0.14%	80
2024 Q4	$1.69M	Buy	+7,400	New	+$1.78M	0.13%	80

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Triglav Skladi's RMD Position: Q1 2026 in Review

Triglav Skladi held its ResMed (RMD) position steady in Q1 2026 at 6,400 shares worth $1.44M. The position accounts for 0.1% of the portfolio, ranked #108.

Triglav Skladi first reported a position in RMD in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.03M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Triglav Skladi held 6,400 shares of ResMed worth $1.44M as of Q1 2026.
Triglav Skladi left its ResMed share count unchanged in Q1 2026.
ResMed made up 0.1% of Triglav Skladi's portfolio in Q1 2026, its #108 holding.
Triglav Skladi first reported a position in ResMed in Q4 2024 and has held it in 6 quarters since.
Triglav Skladi's ResMed position peaked at $2.03M in Q3 2025.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Triglav Skladi's 13F filing for Q1 2026, filed 4 May 2026.